Replies to post #44756 on Biotech Values

[DewDiligence]

>I do not think Boger meant on an ITT basis…<

Having listened to the webcast in which Boger made the comments in question, I’m quiet sure that Boger was referring to the SVR rate on an ITT basis. The ITT number is the number of concern to the FDA, and the question on the webcast was asked in the context of the regulatory strategy for VX-950.

>…it looks like 85% on ITT basis is next to impossible to achieve just because of under-enrollment and misc dropouts…<

In other words, VX-950 is not living up to Boger’s hopes, a point that sell-side analysts are now trying to cover up.

[DewDiligence]

VRTX – Despite the comments in #msg-18686414, I think you are correct in the sense that VRTX will now deemphasize ITT as much as possible. With the early dropout rate in PROVE-1 being as high as it is (even though it is not especially high in an absolute sense), Boger’s Hope as detailed in #msg-11635070 will be mathematically unattainable.